|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00064467 |
This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.
Condition | Intervention | Phase |
Major Depressive Disorder (MDD) |
Drug: Extended-release bupropion (HCl) |
Phase III |
MedlinePlus related topics: | Depression |
ChemIDplus related topics: | Bupropion hydrochloride Bupropion |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study |
Official Title: | See Detailed Description |
Estimated Enrollment: | 268 |
Study Start Date: | June 2003 |
A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Show 24 Study Locations |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | AK130931 |
First Received: | July 8, 2003 |
Last Updated: | October 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00064467 |
Health Authority: | United States: Food and Drug Administration; United States: Food and Drug Administration |
|
|
|
|
|